CAR-T Cell Therapy Against Caludin 18.2 For GI Cancers
2:56
Will zolbetuximab impact the treatment landscape for gastric cancer?
43:59
34 First Line Therapy for HER2- PDL1- CLDN18.2+ GEA
2:17
Claudin 18.2 and FGFR2b as novel targets in gastric cancer
1:00:36
Clinical Trial Updates for Gastric Cancer
1:06:54
Beyond the Horizon in Gastric Cancer: Updated Evidence on How Systemic Therapies Are Redefining Care
1:39
Dr Janjigian on the FDA Approval of Zolbetuximab for CLDN18.2+ Gastric/GEJ Adenocarcinoma
10:01
How Astellas Is Forging a Path in Gastric Cancer Through Its Commitment to Targeted Research
1:44